News

• Subsidy for €1.1 million over a period of 29 months to support the development of a therapeutic vaccination treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
• Funds will be used to demonstrate PoC, establish the clinical relevance of the NMOSD Imotope^TM approach and lead to a Phase I clinical trial 
• NMOSD is a rare and severe autoimmune disease of the central nervous system dominated by inflammation of the optic nerve and spinal cord with an estimated incidence between 1-2 per 100,000

Imcyse joins network of academic researchers, industry representatives and patients in collaboration to fight T1D

Consortium of 40 partners under the framework of the Innovative Medicines Initiative (IMI) offers Imcyse greater access to T1D patient populations, a platform for scientific knowledge exchange and technical approaches to further decipher its MoA

Oral presentation during the session Tolerance Delivery Systems & Trial Design Optimization showcases the value the Company’s novel approach to specifically target immune cells involved in autoimmune diseases 

Imcyse’s insulin-based IMOTOPE^TM has shown promising results in a Phase Ib study in patients with Type-1 diabetes 

With an initial focus on autoimmune diseases, Imcyse’s platform has the potential to address a wide range of indications in the vast field of immunology

Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends

Company’s multiple sclerosis Imotope™ shows promising preclinical efficacy and histology results while eliciting immune responses supporting the proposed mode of action and providing proof of concept

Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action.

Imcyse today announces the appointment of seasoned biotech expert Thomas Taapken as executive chairman and chairman of the board, as part of imminent changes at the company following the recent successful €28M ($31.2M) Series B financing round.

 Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications

Imcyse, who develop active specific immunotherapies for the treatment and prevention of severe chronic diseases, today announces the successful enrolment of 41 patients with recent-onset type 1 diabetes into its first-in-human Phase 1b study.

The double-blind, placebo-controlled, dose-escalation clinical study recruited patients with insulin-dependent type 1 diabetes diagnosed within six months prior to inclusion, from seven European countries (Belgium, Denmark, France, Germany, Lithuania, Sweden and the UK). The trial investigates the safety, the immunological responses and the clinical impact of Imcyse’s unique Imotopes™ technology. An independent data safety monitoring committee review has rated the safety profile so far as excellent. Complete results are expected in summer 2019.

Imcyse SA announces that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) for development of an ImotopeTM, a specific modified peptide, targeting rheumatoid arthritis (RA). Under the terms of the agreement, Pfizer will provide an undisclosed amount to fund the research activities, and Pfizer has an exclusive option to negotiate a license agreement for a limited period following the research activities. Additionally, Pfizer will perform preclinical evaluation of another of Imcyse’s Imotopes targeting multiple sclerosis (MS) to better understand the mode of action of Imcyse's Imotope technology platform. Imcyse will have access to select technology platforms at Pfizer as well as all research results related to this collaboration.